Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
FRA:JIL's 14-Day RSI is ranked better than 68.39% of 1047
companies
in the Drug Manufacturers industry
Industry Median: 51.99
vs FRA:JIL: 46.36
Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Jilin Province Huinan Changlong Bio-pharmacy Co 14-Day RSI Related Terms
FRA:JIL vs ZTS, UTHR: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jilin Province Huinan Changlong Bio-pharmacy Co's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jilin Province Huinan Changlong Bio-pharmacy Co 14-Day RSI vs Drug Manufacturers Industry
Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) has a 14-Day RSI of 46.36 as of Jul. 19, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co and its competitors. According to the industry distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #331 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 31.6%.
Is Jilin Province Huinan Changlong Bio-pharmacy Co's 14-Day RSI too high?
Jilin Province Huinan Changlong Bio-pharmacy Co's current 14-Day RSI is 46.36. The Drug Manufacturers industry median 14-Day RSI is 51.99. Jilin Province Huinan Changlong Bio-pharmacy Co's value of 46.36 is 10.8% below this industry median. Based on the distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #331 out of 1047 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jilin Province Huinan Changlong Bio-pharmacy Co has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Jilin Province Huinan Changlong Bio-pharmacy Co's 14-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #331 out of 1047 companies for 14-Day RSI. This puts Jilin Province Huinan Changlong Bio-pharmacy Co in the upper half of its industry. The industry median 14-Day RSI is 51.99. Jilin Province Huinan Changlong Bio-pharmacy Co's value of 46.36 is 10.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 51.99, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jilin Province Huinan Changlong Bio-pharmacy Co's current 14-Day RSI of 46.36 is 10.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 51.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jilin Province Huinan Changlong Bio-pharmacy Co's current 14-Day RSI is 46.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jilin Province Huinan Changlong Bio-pharmacy Co stock overvalued right now?
Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) has a current 14-Day RSI of 46.36. The stock's GF Value™ is €0.18, compared to a current price of €0.25 — trading 40% above its estimated fair value. The current 14-Day RSI is 46.36 and 10.8% below the Drug Manufacturers industry median of 51.99. Jilin Province Huinan Changlong Bio-pharmacy Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL), the current 14-Day RSI is 46.36 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) Overvalued in 2026?
Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co stock appears to be overvalued.
The current stock price of €0.25 is trading 40% above its estimated GF Value™ of €0.18.
Key valuation signals for FRA:JIL:
14-Day RSI: 46.36
GF Value™: €0.18 vs. price of €0.25 (40% above fair value)
Industry Position: 10.8% below the Drug Manufacturers median (#331 of 1047)
No single metric tells the full story. See the FRA:JIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jilin Province Huinan Changlong Bio-pharmacy Co Business Description
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is principally engaged in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC under the brand names of Changlong and Qing Tong. The company has only one business segment. It generates revenue from the Sales of Chinese medicines and pharmaceutical products. Geographically, it derives its entire revenue from the PRC.
81GF Score
Get the complete analysis for FRA:JIL
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:JIL has been successfully added to your 
